Filing Details
- Accession Number:
- 0000899243-20-000991
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-01-10 17:15:08
- Reporting Period:
- 2020-01-08
- Accepted Time:
- 2020-01-10 17:15:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1743881 | Bridgebio Pharma Inc. | BBIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1758363 | Cameron Turtle | C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-01-08 | 10,000 | $17.00 | 22,630 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-01-08 | 8,005 | $34.17 | 14,625 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-01-08 | 4,802 | $34.71 | 9,823 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-01-08 | 10,000 | $0.00 | 10,000 | $17.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
290,000 | 2029-06-26 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019.
- Represents the weighted average sale price of the shares sold from $33.51 to $34.505 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
- Represents the weighted average sale price of the shares sold from $34.515 to $35.075 per share.
- The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.